HRMY
Harmony Biosciences Holdings, Inc. [HRMY] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
HRMY Stock Summary
Top 10 Correlated ETFs
HRMY
Top 10 Correlated Stocks
HRMY
In the News
HRMY Financial details
Company Rating
-
Market Cap
1.67B
Income
128.85M
Revenue
582.02M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
246
Optionable
No
Shortable
Yes
Earnings
30 Apr 2024
P/E
12.94
Forward P/E
-
PEG
-4.37
P/S
3.52
P/B
4.05
P/C
-
P/FCF
9.12
Quick Ratio
3.9
Current Ratio
4.12
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
2.16
EPS next Y
-
EPS next Q
-
EPS this Y
-29.32%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
149.71%
Revenue Q/Q
5.08%
EPS Q/Q
-28.13%
-
-
-
-
SMA20
9.68%
SMA50
17.24%
SMA100
-8.11%
Inst Own
-
Inst Trans
-
ROA
19%
ROE
33%
ROC
0.3%
Gross Margin
81%
Oper. Margin
37%
Profit Margin
28%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
18.611-39.265
52W High
-9.33%
52W Low
+96.44%
RSI
66
Rel Volume
1.41
Avg Volume
357K
Volume
503.86K
Perf Week
4.71%
Perf Month
14.95%
Perf Quarter
-3.78%
Perf Half Y
-8.13%
-
-
-
-
Beta
0.725
-
-
Volatility
0.79%, 1.81%
Prev Close
-0.31%
Price
35.36
Change
3.6%
Company Profile
- Volume Average 357K
- Market Capitalization 1.67B
- Employee 246
- CEO Dr. Jeffrey M. Dayno M.D.
- Headquarters Plymouth Meeting,PA,US
- IPO Date 2020-08-19
-
Website
https://www.harmonybiosciences.com 
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
